LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,230
تعداد مقالات11,205
تعداد مشاهده مقاله78,023,363
تعداد دریافت فایل اصل مقاله103,587,925
Anvari, Enayat, Talepoor, Atefe, Eshkevar Vakili, Mahsa, Karimi, Narges, Ataollahi, MohammadReza, Najafi, Gelareh, Kabelitz, Dieter, Ahmadi, Iraj, Kalantar, Kurosh. (1401). Comparison of the Antibody Responses Following Vaccination with AstraZeneca and Sinopharm. سامانه مدیریت نشریات علمی, 19(3), 321-329. doi: 10.22034/iji.2022.94298.2300
Enayat Anvari; Atefe Ghamar Talepoor; Mahsa Eshkevar Vakili; Narges Karimi; MohammadReza Ataollahi; Gelareh Najafi; Dieter Kabelitz; Iraj Ahmadi; Kurosh Kalantar. "Comparison of the Antibody Responses Following Vaccination with AstraZeneca and Sinopharm". سامانه مدیریت نشریات علمی, 19, 3, 1401, 321-329. doi: 10.22034/iji.2022.94298.2300
Anvari, Enayat, Talepoor, Atefe, Eshkevar Vakili, Mahsa, Karimi, Narges, Ataollahi, MohammadReza, Najafi, Gelareh, Kabelitz, Dieter, Ahmadi, Iraj, Kalantar, Kurosh. (1401). 'Comparison of the Antibody Responses Following Vaccination with AstraZeneca and Sinopharm', سامانه مدیریت نشریات علمی, 19(3), pp. 321-329. doi: 10.22034/iji.2022.94298.2300
Anvari, Enayat, Talepoor, Atefe, Eshkevar Vakili, Mahsa, Karimi, Narges, Ataollahi, MohammadReza, Najafi, Gelareh, Kabelitz, Dieter, Ahmadi, Iraj, Kalantar, Kurosh. Comparison of the Antibody Responses Following Vaccination with AstraZeneca and Sinopharm. سامانه مدیریت نشریات علمی, 1401; 19(3): 321-329. doi: 10.22034/iji.2022.94298.2300

Comparison of the Antibody Responses Following Vaccination with AstraZeneca and Sinopharm

Iranian Journal of Immunology
دوره 19، شماره 3، آذر 2022، صفحه 321-329    اصل مقاله (1.09 M)
نوع مقاله: Original Article
شناسه دیجیتال (DOI): 10.22034/iji.2022.94298.2300
نویسندگان
Enayat Anvari1؛ Atefe Ghamar Talepoor2؛ Mahsa Eshkevar Vakili2؛ Narges Karimi2؛ MohammadReza Ataollahi3؛ Gelareh Najafi1؛ Dieter Kabelitz4؛ Iraj Ahmadi* 1؛ Kurosh Kalantar* 2، 5
1Department of Physiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran
2Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
3Department of Immunology, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran
4Institute of Immunology, University of Kiel, Kiel, Germany
5Autoimmune Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
چکیده
Background: Vaccines are the most effective way to prevent Coronavirus 2 severe acute respiratory syndrome (SARS-CoV-2).
Objectives: To compare the antibody response of healthy individuals vaccinated with either the AstraZeneca (ChAdOx1 nCoV-19) or the Sinopharm (BBIBP-CorV) vaccine, in those who had no prior infection with SARS-CoV-2.
Methods: Thirty seven participants were included, of which 17 were administered the AstraZeneca (ChAdOx1 nCoV-19) vaccine, while 20 were given the Sinopharm (BBIBP-CorV) vaccine. SARS-CoV-2 neutralizing antibody and anti-receptor-binding domain (RBD) IgG levels were checked 4 weeks after giving the first and the second dose of either vaccine using the enzyme-linked immunosorbent assay (ELISA) technique.
Results: The AstraZeneca (ChAdOx1 nCoV-19) vaccine exhibited a higher levels of anti-(RBD) IgG compared with the Sinopharm (BBIBP-CorV) in both the first (14.51 μg/ml vs. 1.160 μg/ml) and the second (46.68 μg/ml vs. 11.43 μg/ml) doses. About neutralizing Abs, the titer of the antibody was higher in the AstraZeneca (ChAdOx1 nCoV-19) recipients than in the Sinopharm (BBIBP-CorV) subjects after the first (7.77 μg/ml vs. 1.79 μg/ml, p < 0.0001) and the second dose (10. 36 μg/ml vs. 4.88 μg/ml, p < 0.0001).
Conclusions: Recipients vaccinated with two doses of the AstraZeneca (ChAdOx1 nCoV-19) had superior quantitative antibody levels than Sinopharm (BBIBP-CorV)-vaccinated subjects. These data suggest that a booster dose may be needed for the Sinopharm (BBIBP-CorV) recipients, to control the COVID-19 pandemic.
کلیدواژه‌ها
COVID-19؛ Neutralizing Antibody؛ Oxford-AstraZeneca؛ Sinopharm؛ Vaccine
آمار
تعداد مشاهده مقاله: 1,186
تعداد دریافت فایل اصل مقاله: 822


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب